Discussion In France, HPV vaccination coverage tends to decrease. At the end of 2015, the vaccination coverage with three doses reached only 14% in 16-year-old girls (three doses). Although men are also affected by HPV-related diseases such as anal cancer, ano-genital warts, penile cancer or upper aerodigestive tract cancer, vaccine recommendations in France are for girls only. To face the high prevalence of anal cancer and related diseases, the best option is vaccination. Moreover, by offering men a way to prevent diseases against which they do not have any protection yet, universal vaccination could better take into account the ethical issues of prevention. In this paper, we present the point of view of different medical specialties concerning the potential benefit of extending vaccination to boys.
Background
In 2006, the quadrivalent HPV (Human papillomavirus) vaccine (HPV 6, 11, 16 and 18) was approved by the Center for Disease Control and Prevention and the European Medicines Agency and obtained its marketing authorization in both girls and boys.
1,2 HPV vaccination is currently recommended in France in girls from 11-14 years (as part of routine vaccination) to 15-19 years (as part of 'catch-up' vaccination). 3 In May 2016, new HPV vaccination recommendations were published in France for men who have sex with men (MSM) until the age of 26 years. 4 To establish these new recommendations, the Public Health Committee (Haut Conseil de la Santé Publique, HCSP) took into consideration the greater incidence of anal HPV infection and diseases in this population (especially in HIV positive MSM). The vaccine will be available in information centers for screening and diagnosis of sexually transmitted infections (Centre Gratuit d'Information, de Dépistage et de Diagnostic, CEGIDD) and in public centers of vaccination. This new recommendation for MSM marks a significant advance in France, taking into account the burden of HPV diseases in men and by opening first recommendations to males. It is nevertheless regrettable that this recommendation only targets a specific population and that universal vaccination of boys was considered as 'irrelevant from public health point of view in the current context of HPV vaccination'. Moreover, reserving the HPV vaccination of MSM population to CEGIDD and vaccination centers could significantly restrict its access. It is important to remember that all men are highly concerned by HPV infection with >20% of them being infected by at least one known HPV type. 5 No association between age and HPV prevalence is observed in men whereas in women, the highest prevalence of HPV is between 18 and 24 years old, probably due to a stronger immune response. 5 More recently, the issue of extending HPV vaccine to boys has become an ethical concern as limiting vaccination to women might increase stigmatization and psychological burden on women by confirming a perceived inequality of the sexes.
Moreover, recent studies conducted in Norway, Denmark and Austria on the cost-effectiveness impact of vaccinating both girls and boys reported that universal vaccination is a significant cost-effective preventive intervention with faster prevention of cancers and genital warts in both sexes.
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We present here the point of view of different medical specialties regarding the potential benefits of extending HPV vaccination to boys.
Discussion
Gynecologist's point of view: HPV vaccination program is still facing difficulties in France HPV vaccination is a success story with decrease in HPV infection and disease following implementation of national vaccination programs in different countries around the world, but not yet in France. Nevertheless, the real-life impact of HPV vaccination on HPV-related diseases incidence is now well established.
In Australia, where the HPV vaccination coverage for 12-13-year-old girls was >70% in 2011, a study showed the rapid impact of the quadrivalent HPV vaccination in the real-world setting, with a strong reduction in high-grade precancerous cervical lesions (CIN2/3) in young women at the population level. 9 The Australian national HPV vaccination with the quadrivalent vaccine also resulted in significant declines of genital warts in women under 21 years of age (−81.8%) and between 21 and 30 years (−51.1%) 4 years after the introduction of HPV vaccination in 2007. 10 In Europe, other countries also showed an impact of HPV vaccination programs. In Denmark, only 6 years after licensure of the quadrivalent HPV vaccine, a reduced risk of cervical lesions was observed at the population level. The risk of CIN2/3 was indeed significantly reduced among vaccinated women in birth cohorts 1991-94 (Hazard Ratio from 0.27 to 0.56). 11 In England, where a national HPV immunization program was introduced in 2008 using the bivalent HPV 16/18 vaccine, the prevalence of HPV 16/18 infection in 16-to 18-year-old girls decreased from 19.1% prior to the introduction of the immunization program to 6.5% in 2010-12.
In France, HPV vaccination coverages have being continuously decreasing since 2011 and are too low to show any impact on HPV-related diseases in population-based studies. At the end of 2015, the vaccination coverage with three doses reached only 14% in 16-year-old girls. 12 One of the most common reasons to explain this decrease is fear triggered by several public debates about 'hypothetical adverse effects' after HPV vaccination even if no causal association has been demonstrated. However, analyses of clinical trial and post-licensure safety data have not identified safety concerns associated with HPV vaccination. 13 The results of a large study conducted by the French National Agency for Medicines and Health Products Safety in France (covering 2.2 million girls aged 13-16) about the risks of occurrence of autoimmune diseases after HPV vaccination are clear. The study focused on 14 autoimmune diseases, including multiple sclerosis. During follow-up, it has not been demonstrated overall increase in risk of occurrence of these 14 diseases in vaccinated girls. 14 Overall, all efficacy and safety data available worldwide converged on the same conclusion: the risk/benefit ratio of HPV vaccines remains favorable.
The low vaccine coverage could also be explained by the wording of initial French recommendations, which closely connected HPV vaccination and initiation of sexual activity hence jeopardizing its implementation and acceptability. Initially, HPV vaccination targeted all girls aged 14 with a catch-up vaccination for girls between 15 and 23 years of age before the start or during the first year of their sexual activity. 15 This recommendation was not optimal for different reasons. First, HPV vaccine was the only vaccine recommended at the age of 14, no other vaccine being scheduled at this age. Secondly, girls aged 14 do not often consult: they generally do not see their pediatrician any longer and they do not see their General Practitioner (GP) very often. Last, the condition about sexual activity for the catch-up vaccination represented a difficulty for GPs and a barrier for vaccine acceptance by parents. In order to facilitate HPV vaccination acceptance, the National French Health Authorities decided in 2013 to lower the age of HPV vaccination from 14 to 11-14 years to benefit from the dTPca booster vaccination already scheduled at this age and to remove the sexual activity condition.
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The next step could be to extend HPV vaccination to boys in order to generalize this vaccination and integrate it in the immunization schedule of all adolescents (boys and girls) in the same way as it is for the dTPca booster vaccination. As noted, providing vaccination to adolescents is challenging because they make infrequent healthcare visits. Coadministration of HPV vaccines with other vaccines recommended in young adolescents could facilitate adherence to recommended vaccination regimens.
School-based programs seem to be efficient in the case of HPV to reach a high vaccination coverage. For example, Australia implemented a school-based program in 2007 and achieved an average three-dose coverage for girls aged 15 of 72% by 2009. 16 The success of the school-based program strategy compared with alternative strategies was also confirmed in a systematic review. 17 To illustrate the potential benefits of universal HPV vaccination, the story of rubella vaccination provides an instructive example. 18 Rubella vaccination was originally reserved for girls aged 12-13 with the monovalent Rudivax ® vaccine. However, control of rubella congenital disease was reached only after implementation in 1986 of a universal vaccination of both genders (boys and girls) with a combined vaccine (measles, mumps, rubella or MMR), which allowed to reach a high vaccine coverage.
If boys were immunized against HPV, it would decrease the circulation of the virus in the population and for unvaccinated girls reduce the risk of being infected via herd protection. Herd protection was already observed in Australia where a high HPV vaccination coverage was reached with a reduction of HPV-related genital warts in the unvaccinated population. 19 Results of mathematical models show that HPV vaccination extension to boys can achieve a further reduction of cervical cancers. 20 Using an individual-based transmissiondynamic model of partnership formation and dissolution to catch the impact of several scenari while extending the vaccine to boys, 21 the authors reported the incremental impact of vaccinating boys on HPV prevalence in both sexes and found that the impact was higher when the vaccine coverage was low among girls.
Proctologist's point of view: the universal HPV vaccination could protect boys against anal cancer HPV infections and HPV-related diseases affect both sexes but the burden of disease in males is often underestimated. Nevertheless, men are also affected by HPV-related diseases such as anal cancer, ano-genital warts and penile cancer.
Anal cancer incidence is increasing by~2% each year in the general population. 22 In France, the anal cancer incidence rate is 0.2-0.7 per 100 000 men and 0.7-1.2 per 100 000 women with~900 new cases per year. 23 The incidence rate is 30 to 100 times higher among immunosuppressed patients and among men who have sex with men (MSM). 24 In this population, the incidence is estimated to be equivalent to that of cervical cancer in women before the implementation of screening. Existing treatments for anal cancer have a limited efficacy and are traumatic for the patient. In case of chemotherapy treatment failure, the consequences of perineum surgical ablation are harmful. Even after therapeutic success, anal incontinence, proctitis and radiation-induced anal dermatitis are unfortunately frequent.
In addition to anal cancer, anal warts and anal precancerous lesions (Anal Intraepithelial Neoplasias or AINs) are also a clinical preoccupation especially because of their high prevalence. Previous studies reported indeed that 23% of all HIV-infected patients develop anal warts 25 and that 23 000 new cases of genital warts occur every year in France. 26 Other studies showed that the prevalence of anal dysplasia varies from 12% to 60% in the general population [27] [28] [29] and from 46% to 93% among HIV-infected patients. 28, 30, 31 AINs treatments are very cumbersome and painful with iterative destruction with electric knife often requiring 1-2 months of healing. The recurrence rate is significant and this repetitive mutilation often lasts several years with no certainty about viral eradication. Moreover, the impact on patients' sexuality is strong with long-term sexual abstinence, social exclusion and substantially decreased quality of life. 32 No organized screening exists for this cancer and diagnosis is often delayed. Like cancers of the cervix, most cases of anal cancers (around 97%) are associated with HPV infection and the proportion of anal cancers associated with HPV 16/18 is high (around 80%). 33 To face the high prevalence of anal cancer and related diseases, the best option is vaccination. Quadrivalent vaccine, which demonstrated a 75% efficacy against vaccine-type related AIN2/3, 34 is indicated for the prevention of HPV-6/11/16/18-related anal cancer and anal precancerous lesions since August 2014.
ENT's point of view: universal HPV immunization could also protect boys against HPV-related head and neck cancers (oropharyngeal cancers)
In 2012, 14 638 new cases of upper aerodigestive tract (UADT) cancers were diagnosed in France with 74% of them among men. 35 Around 25% of these cancers are HPVrelated. 36 The HPV-related UADT cancer is different from the alcohol-smoking UADT cancer. During the past two decades, in developing countries, HPV-related UADT cancer incidence increased and non-HPV oropharyngeal cancer incidence decreased thanks to the decline of alcohol and cigarette consumption. 37 Cancers of the oropharynx, including tonsil and base of tongue cancers are those with the highest proportion of HPV-positive tumors (35-55% HPV positive in Western countries, 46% in France). 38 No screening method for UADT cancers is currently available and most of them are consequently diagnosed at later stages. These cancers are associated with a high mortality even after treatment, with a 5-year survival rate below 50%. Moreover, treatment was shown to be associated with a deteriorated quality of life. 39 The causal link between head and neck cancers and HPV is increasingly documented but cannot be established solely on the presence of viral DNA. However, HPV 16 has been classified as an oncogene for oropharyngeal cancers. A study reported indeed a 274-fold increased risk of developing an oropharyngeal cancer in patients with positive HPV-16 serology. 40 This strong association suggests a potential benefit of HPV vaccination. Thus, even if no results of vaccine efficacy are expected (for reasons of feasibility of clinical trials) it is reasonable to believe that vaccination may widely contribute to reduce the incidence of oropharyngeal cancers. 41 
Conclusion
Universal vaccination (for both genders) is already recommended in Canada, in the USA and in Australia since 2013. In Europe, Austria (in 2013), Switzerland (in 2015) and more recently Norway, Italy (nine regions) and Germany (Saxony only) are the first countries to have recommended, the universal vaccination for both genders. To date, no study on the direct impact of extending the vaccine to boys has been reported due to the recent shift. However, several recent cost-effectiveness studies are in favor with this policy decision. [6] [7] [8] In France, the public health committee (HCSP) recently decided to extend HPV vaccination to MSM under 26 years. Such a policy could be confronted with problems of feasibility (how to vaccinate before exposure to risk, and therefore before manifestation of the sexual preference?), ethics issues and controversies about equality of access.
By offering all men a way to prevent diseases against which they do not have any protection yet, universal vaccination could better take into account the ethical issues of prevention. In addition, HPV vaccination, becoming a routine vaccination, could benefit from better public acceptance, which would improve vaccine coverage, especially in countries with low vaccination rates. 42 Based on the large body of evidence showing favorable benefit-risk assessment, we sincerely hope that routine HPV vaccination in both genders will be recommended in France.
